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Abstract A substantial number of prospective epidemiologi-
cal studies have been conducted to investigate the association
between biomarkers of inflammation and immune function
and risk of colorectal cancer. Although pre-diagnostic concen-
trations of these biomarkers, especially C-reactive protein,
have been associated with a higher risk of colorectal cancer
in some studies, this association does not seem to have a
robust support without hints of bias. Future prospective stud-
ies should evaluate multiple inflammatory biomarkers with
longitudinal measures over the follow-up taking advantage
of new multiplex cytokine quantification arrays and use more
sophisticated joint or biomarker pattern statistical approaches
to capture the complex and dynamic interplay between bio-
markers and risk of colorectal cancer. Large collaborative con-
sortia andMendelian randomization studies should be encour-
aged to diminish the threat of biases and improve the reliabil-
ity of this literature.
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Introduction
Colorectal cancer (CRC) is the third most commonly diag-
nosed cancer worldwide that accounted for 1.36 million new
cases and 694,000 deaths in 2012 [1]. CRC develops through
a gradual accumulation of genetic, both inherited and somatic,
and epigenetic changes, leading to the transformation of nor-
mal colonic mucosa into invasive cancer. Approximately 70 to
90 % of CRCs arise from adenomatous polyps (adenomas)
[2]. The risk of CRC increases with age especially after the
age of 50 years, and the risk is also increased by certain high-
penetrance inherited genetic mutations (familial adenomatous
polyposis and hereditary non-polyposis colorectal cancer),
several low penetrance mutations [3], a personal or family
history of colorectal neoplasia, or a personal history of inflam-
matory bowel diseases (IBD) [4]. Several modifiable factors
are also associated with increased risk of CRC, including obe-
sity, physical inactivity, smoking, heavy alcohol consumption,
type II diabetes, and a diet high in red or processedmeat, while
the use of aspirin or other non-steroidal anti-inflammatory
drugs (NSAIDs) lowers risk [5].
Systemic inflammation is a pathway through which several
of the aforementioned risk factors may lead to colorectal neo-
plasia. For example, obesity is associated with a state of
chronic inflammation induced by excessive production of
storage lipids and high circulating concentrations of glucose,
both of which create a proinflammatory oxidative environ-
ment that has been associated with colorectal carcinogenesis
[6, 7]. Adipocytes constitutively express the proinflammatory
cytokine tumor necrosis factor α (TNF-α), and TNF-α
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expression in adipocytes is markedly increased in obese ro-
dents [8].
However, the link between inflammation and colorectal
neoplasia is not only substantiated at a systemic level, and it
has been further hypothesized that sporadic colorectal neopla-
sia arises from colonic areas with chronic subclinical inflam-
mation. Several lines of evidence implicate chronic inflamma-
tion as a key predisposing factor to colorectal cancer in IBD
[9]. First, the risk for developing colorectal cancer increases
with longer duration of colitis. Second, the more colonic sur-
face is involved with colitis, the greater the colon cancer risk.
Third, evidence is mounting to suggest that anti-inflammatory
medications, especially 5-aminosalicylates, can reduce the de-
velopment of colorectal dysplasia and cancer in IBD. The
evidence directly implicating colonic inflammation as a key
predisposing factor to sporadic colorectal neoplasia is weaker
compared to the evidence for colitis-associated colorectal neo-
plasia. Some, but not all, clinical studies have shown that
colorectal adenoma and cancer patients had higher fecal
calprotectin levels, a direct measure of gastrointestinal muco-
sal inflammation, than normal subjects [10–12]. Colonic mi-
crobiota are being increasingly recognized as important con-
tributors to the health of the gastrointestinal tract and may not
only lead to CRC development via modulation of the gut
barrier function and initiation of inflammation at the colonic
epithelium but could also promote systemic inflammation via
leakage of bacterial endotoxins into the circulation [13, 14].
The aim of this review is to examine and critically appraise
the associations in the literature between biomarkers of in-
flammation and immune function and risk of CRC and
through which infer about the strength of the evidence linking
systemic and/or chronic low-grade colorectal inflammation to
colorectal carcinogenesis.
Circulating Concentrations of Inflammatory
Biomarkers and Risk of CRC
C-Reactive Protein
C-reactive protein (CRP) is a sensitive but non-specific sys-
temic marker of inflammation that is produced mainly in the
liver in response to cytokines released by phagocytes during
infection, trauma, surgery, burns, tissue infarction, advanced
cancer, and chronic inflammatory conditions [15]. The circu-
lating concentrations of CRP in healthy individuals are low,
usually below 1 mg/L, but they sharply increase in acute in-
fection reaching concentrations well above 10mg/L. The half-
life of CRP is 19 h [16].
A total of 18 prospective epidemiological studies have
been conducted to date to investigate the association of
pre-diagnostic high-sensitivity CRP concentrations with
risk of CRC (Table 1) and have been summarized in three
meta-analyses [25, 37, 38•]. Fourteen out of 18 studies
included in the most recent meta-analysis showed a higher
risk of CRC with higher concentrations of CRP, but only
six of them yielded statistically significant results [38•].
The summary random effects relative risk of CRC per
one unit change in the natural logarithm (ln) of CRP
was 1.12 (95 % CI, 1.05–1.21), but substantial heteroge-
neity was evident among the studies (P heterogeneity,
0.006; I2, 52 %) [38•]. The summary association was sta-
tistically significant for colon cancer (RR, 1.13; 95 % CI,
1.05–1.21) but not for rectal cancer (RR, 1.03; 95 % CI,
0.90–1.17), although there was not a statistically signifi-
cant difference between the estimates by anatomical loca-
tion. Moreover, the summary association for CRP and
CRC appeared stronger in men (RR, 1.18; 95 % CI,
1.06–1.30) than in women (RR, 1.05; 95 % CI, 0.96–
1.16), but again the confidence intervals of the associa-
tions by sex overlapped. The results of this meta-analysis
were consistent to the results of prior meta-analyses, in-
cluding the one from our group [37].
The first prospective study was published in 2004 from
the CLUE II cohort of Washington County, MD, with 172
CRC cases and 342 matched controls and found a twofold
statistically significant increase in the risk of colorectal
cancer comparing persons with the highest versus lowest
fourth of C-reactive protein [17]. A subsequent study by
Zhang and colleagues was performed within the Women’s
Health Study, which recruited female health professionals,
and found an almost statistically significant inverse asso-
ciation between CRP and colorectal cancer [18]. The two
largest studies in the field were published from the Euro-
pean Prospective Investigation into Cancer and Nutrition
(EPIC) in 2010 and the Women’s Health Initiative obser-
vational cohort in 2013 with approximately 1000 CRC
cases each, but observed weak and borderline statistically
significant associations [28, 34]. A new study was pub-
lished in 2014, not included in the published meta-analy-
ses, using the NHANES III data and found an imprecise
but statistically significant increased risk of colorectal can-
cer mortality comparing CRP above 1 mg/dL versus un-
detectable concentrations, but the study did not use a
high-sensitivity CRP assay and observed only 59 CRC
deaths [39].
The evidence linking CRP concentrations with colorectal
adenoma development, a precursor in the natural history of
colorectal neoplasia, is weaker. Pre-diagnostic CRP concen-
trations were not associated with colorectal adenoma in our
study in the CLUE II cohort [40]. A subsequent case-control
study nested in the Prostate, Lung, Colorectal, and Ovarian
Cancer Screening Trial observed a statistically significant
15 % reduction in risk per unit increase in ln CRP [41], which
could reflect an attempt by the host to suppress tumor forma-
tion. Other studies observed mixed results from null
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Table 1 Characteristics of studies investigating the association between circulating concentrations of inflammatory biomarkers (per one unit change in
the ln-transformed concentrations of CRP, IL-6, and TNF-α) and the risk of colorectal cancer
Author, year Country Population Study
design
No. of
cases
No. of controls/
population
Inflammatory biomarkers RR (95 % CI)
Erlinger, 2004 [17] USA CLUE II NCC 172 342 CRP Colorectum 1.27
(1.03–1.57)
Colon 1.37 (1.08–1.74)
Rectum 0.99
(0.61–1.59)
Zhang, 2005
[18]
USA WHS Cohort 169 27,913 CRP Colorectum 0.89
(0.76–1.04)
Colon 0.80 (0.39–1.67)
Rectum 0.52
(0.28–0.99)
Ito, 2005 [19] Japan JACC NCC 141 327 CRP Colorectum 1.11
(0.94–1.31)
Colon 1.11 (0.90–1.37)
Rectum 1.13
(0.86–1.49)
Il’yasova, 2005 [20] USA HABCS Cohort 41 2438 CRP IL-6 TNF-α Colorectum 1.44
(1.03–2.02)
Colorectum 1.44
(0.90–2.31)
Colorectum 0.90
(0.42–1.94)
Trichopoulos,
2006 [21]
Greece EPIC-Greece NCC 48 996 CRP Colorectum 1.19
(0.81–1.74)
Colon 1.32 (0.84–2.08)
Rectum 1.41
(0.94–2.11)
Siemes, 2006 [22] Netherlands Rotterdam
Study
Cohort 189 6273 CRP Colorectum 1.04
(0.88–1.22)
Colon 1.15 (0.71–1.88)
Rectum 0.70
(0.50–0.99)
Otani, 2006 [23] Japan JPHC NCC 375 750 CRP Colorectum 1.11
(0.95–1.30)
Colon 1.06 (0.87–1.29)
Rectum 1.19
(0.90–1.58)
Gunter, 2006 [24] Finland ATBC NCC 130 260 CRP Colorectum 1.33
(1.05–1.69)
Colon 1.32 (0.97–1.79)
Rectum 1.49
(1.02–2.17)
Heikkila, 2009 [25] UK BWHHS Cohort 32 3274 CRP IL-6 Colorectum 0.97
(0.70–1.34)
Colorectum 0.92
(0.53–1.60)
Heikkila, 2009 [25] UK Caerphilly Cohort 41 1144 CRP IL-6 Colorectum 0.89
(0.66–1.22)
Colorectum 0.71
(0.41–1.23)
Allin, 2009 [27] Denmark CCHS Cohort 191 10,082 CRP Colorectum 1.52
(0.86–2.67)
Aleksandrova,
2010 [28]
Europe EPIC NCC 1096 1096 CRP Colorectum 1.06
(0.99–1.13)
Colon 1.09 (1.01–1.18)
Rectum 0.99
(0.88–1.10)
Chan, 2011 [29] USA NHS NCC 280 555 CRP IL-6
252 Curr Colorectal Cancer Rep (2015) 11:250–258
association in a case-control study in Hawaii to a higher risk of
large adenomas for participants in the highest category of CRP
concentrations in a case-control study in Japan [26, 42].
Given that high-sensitivity CRP is a circulating marker for
inflammation, the lack of a consistent association with colo-
rectal neoplasia raises questions on its use as a marker of the
inflammatory process associated with colorectal cancer. When
we investigated whether increased CRP is a marker of colonic
inflammation, we found no such association in a colonoscopy-
based study [43•], which implies that CRP may be marking
systemic factors (e.g., obesity) that influence colorectal cancer
risk or that the observational associations between CRP and
colorectal cancer may be afflicted by biases.
In 2012, our group critically appraised the literature of 98
biomarkers and cancer risk evaluating 847 individual studies
to shed light on the existence of potential biases and identify
associations with robust evidence for their presence [44••, 45].
We concluded that the association between CRP and CRC
was not among the robust associations without suggestion of
bias, as evidence of large between-study heterogeneity, small-
study effects (i.e., smaller studies tended to give larger esti-
mates of effect size compared with larger studies), and excess
statistical significance (i.e., the observed number of studies
with nominally statistically significant results was greater than
the expected number, calculated based on the statistical power
to detect a plausible effect) was identified [44••]. It is thus
Table 1 (continued)
Author, year Country Population Study
design
No. of
cases
No. of controls/
population
Inflammatory biomarkers RR (95 % CI)
Colorectum 0.85
(0.67–1.09)
Colorectum 1.09
(0.77–1.55)
Lee, 2011 [30] Korea Health exam
records
Cohort 158 80,781 CRP Colorectum 1.59
(1.13–2.22)
Prizment, 2011 [31] USA ARIC Cohort 166 9836 CRP Colorectum 1.36
(1.06–1.75)
Colon 1.38 (1.05–1.82)
Rectum 1.12
(0.64–2.00)
Van Hemelrijck,
2011 [32]
Sweden AMORIS Cohort 480 102,749 CRP Colon 1.00 (0.92–1.07)
Ho, 2012 [33] USA WHI-OS NCC 457 841 IL-6 TNF-α Colorectum 0.91
(0.60–1.38)
Colorectum 0.77
(0.51–1.17)a
Toriola, 2013 [34] USA WHI-OS NCC 988 988 CRP Colorectum 1.09
(0.97–1.24)
Colon 1.13 (0.99–1.30)
Rectum 0.86
(0.62–1.20)
Song, 2013 [35] USA HPFS NCC 274 532 CRP IL-6 Colorectum 1.25
(0.94–1.67)
Colon 0.97 (0.68–1.39)
Rectum 0.88 (0.49–1.56)
Colorectum 1.45
(1.05–2.00)
Wu, 2013 [36] China SMHS NCC 288 576 CRP Colorectum 1.65
(1.10–2.48)
Colon 1.90 (1.12–3.23)
Rectum 1.29
(0.66–2.54)
CRP C-reactive protein; IL-6 interleukin-6; TNF-α tumor necrosis factor alpha; NCC nested case-control study; RR relative risk;WHSWomen’s Health
Study; JACC Japan Collaborative Cohort Study; JPHC The Japan Public Health Center-based Prospective Study; ATBC Alpha-Tocopherol Beta-
Carotene Cancer Prevention Study;CCHSCopenhagen City Heart Study;EPICEuropean Prospective Investigation into Cancer andNutrition; AMORIS
Apolipoprotein Mortality RISk study; ARIC Atherosclerosis Risk in Communities study; NHS Nurses’ Health Study; BWHHS British Women’s Heart
and Health Study; HPFS Health Professionals Follow-up Study; HABCS Health, Aging and Body Composition cohort; WHI-OS Women’s Health
Initiative Observational Study; SMHS Shanghai Men’s Health Study
aAssociation reported for top vs. bottom quartile
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probable that the statistically significant studies in this field
are subject to selective reporting or other biases. Selective
reporting bias may emerge when there are many analyses that
can be performed (using, for example, different adjustments
for confounders or models with different statistical terms for
CRP and confounders), but only the analysis with the most
statistically significant result is presented [46, 47]. Studies
demonstrating an association between inflammatory markers
and colorectal neoplasia may also have reverse causation bias
due to clinically undetected neoplasia at the time of blood
collection. Inadequate control for potential confounders may
also influence the findings of observational studies, as obesity,
physical activity, and use of aspirin or non-steroidal anti-in-
flammatory drugs are each strongly related to both inflamma-
tory activity and CRC risk.
Further evidence suggesting a lack of a causal link between
CRP and colorectal neoplasia comes from candidate gene as-
sociation studies that have observed mixed results for the as-
sociation of genetic variants in the CRP gene and colorectal
cancer risk [22, 48–52] and genome-wide association studies
that have not identified CRP variants to be associated with
CRC risk [3]. Mendelian randomization analyses have used
single-nucleotide polymorphisms in CRP and/or genetic
scores thereof as instruments of the circulating CRP concen-
trations in order to correct for potential biases of the observa-
tional association and have generally reported null results [50,
53, 54], except for a study in EPIC where genetically twofold
higher CRP concentrations were associated with higher risk of
CRC, but this result lost nominal statistical significance using
alternative definitions of instrumental variables [49]. Howev-
er, all these Mendelian randomization studies have used sub-
optimal sample sizes with number of cancer cases below 900
[55]. Future studies should take advantage of recent develop-
ments in this field, i.e., the use of efficient designs and
methods to adjust for violation of assumptions [56–58], to
elucidate whether potential causal associations exist between
inflammatory biomarkers and cancer risk.
Interleukin-6
Interleukin-6 (IL-6) is a multifunctional cytokine produced by
a variety of hematopoietic and non-hematopoietic cells [59]
and exerts a proinflammatory role by acting either on a trans-
membrane type 1 cytokine receptor or by binding to a soluble
IL-6 receptor (sIL6R). IL-6 upregulates several acute-phase
proteins such as CRP, fibrinogen, α1-antitrypsin, and serum
amyloid A [60]. There is ample mechanistic evidence suggest-
ing an involvement of IL-6 in CRC development. In vivo
experiments on wild-type mice have shown that IL-6 is sig-
nificantly augmented at the colonic tumor environment, and
the growth of colon tumors was suppressed when the mice
were treated with antibodies against IL6R [61]. However, re-
sults from epidemiological studies regarding the association of
circulating IL-6 concentrations and risk of subsequent colo-
rectal cancer development have been sparse, as only six pro-
spective studies exist (Table 1) [20, 25, 29, 33, 35].
II’yasova and colleagues found that serum IL-6 concentra-
tions were not statistically significantly associated with the risk
of colorectal cancer in the Health Aging andBody Composition
Cohort [20]. Similarly, no association was observed in two
prospective studies in the UK published in 2009 [25], but the
latter three studies included only 30 to 40 colorectal cancer
cases. Chan et al. used 279 cases from the Nurses’Health Study
but also did not observe a statistically significant association
[29], and another large publication with 413 cases from the
Women’s Health Initiative observational cohort yielded a sim-
ilar not significant finding [33]. Only a recent paper from the
Health Professionals Follow-up Study observed a borderline
significant increased risk of colorectal cancer with higher IL-6
concentrations, but this association did not remain significant
when the first 2 years of follow-up were excluded [35]. When
the results of the latter six studies were synthesized in a meta-
analysis, a non-significant summary relative risk was observed
(RR, 1.10; 95 % CI, 0.88–1.36) per one unit change in ln IL-6
without substantial between-study heterogeneity (P heterogene-
ity, 0.18; I2, 35 %) [38•].
The epidemiological studies have not in general reported
results by tumor location, except for the Health Professionals
Follow-up Study that observed a statistically significant in-
creased risk of colon cancer with higher IL-6 concentrations,
but the estimate was attenuated and not statistically significant
anymore after excluding cases that occurred within 2 years of
the baseline blood draw [35]. No association was observed for
rectal cancer risk. Very recently, we finalized an analysis of
pre-diagnostic plasma IL-6 concentrations and risk of colorec-
tal cancer in the CLUE II cohort using 173 incident colorectal
cancer cases and 345 matched controls. We observed that
participants in the highest tertile of IL-6 concentration had a
statistically significant and greater than twofold higher risk of
colon cancer compared to participants in the bottom tertile
(Tsilidis KK, personal communication). This association
remained statistically significant after excluding cases that oc-
curred within 2 or 5 years from the start of follow-up.
The association between IL6 genetic polymorphisms and
risk of CRC has been evaluated in several candidate gene stud-
ies with largely null results [48, 62–64]. The -174G>C poly-
morphism (rs1800795) has been widely evaluated, and a recent
meta-analysis of 11 studies incorporating 6481 cases and 7935
controls did not find a statistically significant association [65].
TNF-Alpha
TNF-α is another pleiotropic cytokine that is elevated in response
to infection and tissue damage and has been shown to be in-
volved in the pathogenesis of IBD [66]. However, scarce epide-
miological evidence exists about a potential association between
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pre-diagnostic TNF-α concentrations and risk of colorectal can-
cer (Table 1). No statistically significant associations have been
observed in two North American prospective studies [33, 67].
Consistent with this evidence, Vaughn and colleagues reported a
null association between TNF-α and colon adenoma in a
colonoscopy-based case-control study [68]. A surrogate marker
for TNF-α, soluble tumor necrosis factor receptor 2 (sTNFR-2),
that is more stable in stored frozen samples and less influenced
by diurnal variation was significantly associated with increased
risk of CRC in women in the Nurses’ Health Study [29], but no
association was observed in two subsequent studies either in
women or in men [35, 69]. Concentrations of sTNFR-2 were
not associated with colorectal adenoma recurrence in patients
with a prior adenoma [70]. Candidate gene association studies
have not observed statistically significant findings between SNPs
in TNFa, especially rs1800629, and risk of colorectal cancer [48,
62–64].
Other Inflammatory Biomarkers
The literature evidence regarding the association of circulating
concentrations of inflammatory biomarkers, other than CRP,
IL-6, and TNF-α, and the risk of colorectal cancer is very
sparse. Serum amyloid A (SAA) is a non-specific inflamma-
tory marker produced in the liver in response to infection,
trauma, and other inflammatory states and has been hypothe-
sized to be a more sensitive marker of inflammation over CRP
for certain diseases [15, 71]. However, pre-diagnostic concen-
trations of SAAwere not associated with CRC in theWomen’s
Health Initiative Observational Study [34]. Macrophage in-
hibitory cytokine 1 (MIC-1) is another novel inflammatory
biomarker, which was positively associated with colorectal
cancer risk in the Nurses’ Health Study and the Health Pro-
fessionals Follow-up Study [72]. Fibrinogen concentrations
were positively associated with risk of colon cancer in another
prospective study in the USA, but white blood cell count, von
Willebrand factor, factor VIII, and albumin did not yield sta-
tistically significant associations [31]. However, white blood
cell count was associated with an increased risk of colon can-
cer in a Swedish and a Korean prospective study [32, 73]. A
recent nested case-control study in the EPIC cohort studied the
association of neopterin, a biomarker of cellular immune ac-
tivity, with the risk of colorectal cancer and found evidence of
a U-shaped association, but neopterin has been shown to exert
pleiotropic effects on cellular aging, oxidative stress, and in-
flammation [74]. Another pleiotropic biomarker, advanced
glycation end products (AGE), that accumulates during aging
and induces oxidative stress and inflammation has been inves-
tigated in the prospective Alpha-Tocopherol, Beta-Carotene
Cancer Prevention (ATBC) study. High pre-diagnostic con-
centrations of AGE were not associated with colorectal cancer
risk, but high concentrations of the soluble AGE receptor
yielded a lower risk [75].
The adipose tissue is an active endocrine organ that secretes
several cytokines and hormones, collectively termed
adipokines (e.g., leptin, adiponectin, and resistin), which have
been demonstrated to have pro- or anti-inflammatory functions.
The association between adipokines and colorectal cancer risk
has been investigated in several epidemiological studies, the
results of which have been mixed [76]. The description and
critical appraisal of this evidence are out of scope for the current
review, as these adipokines have many pleiotropic effects (e.g.,
energy homeostasis, insulin signaling, and vascular reactivity)
and cannot be considered primarily inflammatory biomarkers.
Calprotectin is a calcium- and zinc-binding protein released
by activated innate immunity cells. It is found in cells, tissues,
and fluids throughout the body and has been studied in a
variety of inflammatory conditions [77]. Fecal calprotectin
has been hypothesized to be a direct measure of gastrointesti-
nal mucosal inflammation [78, 79]. Some clinical studies have
shown that colorectal adenoma and cancer patients had higher
fecal calprotectin levels than normal subjects, but a recent
meta-analysis reported a non-statistically significant associa-
tion between fecal calprotectin and colorectal neoplasia [12].
Conclusions and Future Directions
The overall literature evidence for an association between in-
flammatory biomarkers and risk of colorectal cancer is incon-
clusive. Although concentrations of inflammatory bio-
markers, especially CRP, have been associated with colorectal
cancer risk in some studies, this association does not seem to
have a robust support without hints of bias (e.g., selective
reporting, reverse causation, residual confounding). This does
not necessarily mean that these biomarkers are not truly asso-
ciated with colorectal cancer, but there is still substantial un-
certainty about them. If any potential causal association is
identified in the future between an inflammatory biomarker
and risk of colorectal cancer, then this might lead to the po-
tential development or repurposing of drugs targeting recep-
tors of inflammatory markers.
There are several ways to improve this evidence in the fu-
ture. First, the measurement and estimation of a single biomark-
er and colorectal cancer association in most of the existing
studies do not consider the complex synergisms among the
many inflammatory biomarkers. Recent developments in serum
cytokine quantification technology include multiplex arrays
that can measure multiple biomarkers in each sample and better
evaluate the complex and dynamic nature of inflammatory re-
sponses with substantial cost and sample savings [80]. When
many biomarkers are available per participant, then a more
sophisticated joint or biomarker pattern statistical approach or
an exposure-wide association study could be used to assist in
capturing the complete picture of the biomarker and cancer
association. Some of these methods have been used in the
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existing literature, but their use is still sparse and their results are
inconsistent and imprecise [31, 32, 34, 69, 81]. Second, the
single measurement of an inflammatory biomarker in time does
not represent an average concentration over time and may lead
to regression dilution bias. Future studies should better ascertain
how long-term exposure to concentrations of inflammatory bio-
markers may be related to colorectal cancer risk, as reports have
shown that the long-term stability of inflammatory biomarkers
is good but not perfect [82, 83].
Third, large collaborative consortia should be encouraged
in this field. The use of standardized definitions and protocols
for exposures, outcomes, confounders, and statistical analyses
may diminish the threat of biases and improve the reliability of
this literature. Many of the biases may be further lessened if
studies were more completely and transparently reported ac-
cording to published guidelines, such as the Strengthening the
Reporting of Observational Studies in Epidemiology state-
ment and its extension for Molecular Epidemiology [84–86].
Statistical significance testing should not be used as a criteri-
on, either from authors or editors, for publication of biomarker
studies. Future Mendelian randomization studies could also
assist in elucidating potential causal associations.
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